Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2018-06-27 19:52:13
Reporting Period:
Accepted Time:
2018-06-27 19:52:13
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1649989 Oncobiologics Inc. ONS () 4
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1527197 Kenneth Bahrt C/o Oncobiologics, Inc.
7 Clarke Drive
Cranbury NJ 08512
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-06-25 7,700 $0.85 47,120 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
  1. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units ("RSUs"). This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
  2. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.845 to $0.8525, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. Includes 14,493 shares of the Issuer's common stock subject to RSUs that will vest on 6/22/19, the four-year anniversary of the 6/22/15 grant date, subject to continued service through such date.